David Meads, PhD

University of Leeds, United Kingdom

Poster(s):

• 1415 - Health-related quality of life in patients with previously untreated chronic lymphocytic leukaemia treated with ibrutinib and rituximab or fludarabine, cyclophosphamide and rituximab: patient-reported outcomes from the multicentre, open-label, randomised, phase 3 FLAIR trial